Rafael Holdings, Inc. Announces Board Appointments
June 14, 2021 at 04:45 pm EDT
Share
Rafael Holdings, Inc. announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc.; and Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir Bio. Ameet Mallik has over 16 years of experience at Novartis, where he most recently served as Executive Vice President and Head, U.S. Oncology responsible for commercial and medical operations in the United States. Shannon Thyme Klinger serves as Chief Legal Officer of Moderna. Ms. Klinger also serves on Moderna's Executive Committee and as Corporate Secretary. Before joining Moderna, Ms. Klinger served as Chief Legal Officer and a member of the Executive Committee at Novartis from 2018 to 2021. Mark McCamish, MD, Ph.D., is President and Chief Executive Officer at IconOVir Bio, and previously served as the President and Chief Executive Officer of Forty Seven, Inc., where he led the company through critical phases of clinical development and its acquisition by Gilead.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Companyâs real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).